Charles Schwab’s Tarsus Pharmaceuticals TARS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $13.3M | Buy |
329,297
+38,979
| +13% | +$1.58M | ﹤0.01% | 1875 |
|
|
2025
Q1 | $14.9M | Sell |
290,318
-3,382
| -1% | -$174K | ﹤0.01% | 1770 |
|
|
2024
Q4 | $16.3M | Buy |
293,700
+3,691
| +1% | +$204K | ﹤0.01% | 1799 |
|
|
2024
Q3 | $9.54M | Buy |
290,009
+28,130
| +11% | +$925K | ﹤0.01% | 2048 |
|
|
2024
Q2 | $7.12M | Buy |
261,879
+39,882
| +18% | +$1.08M | ﹤0.01% | 2196 |
|
|
2024
Q1 | $8.07M | Buy |
221,997
+3,335
| +2% | +$121K | ﹤0.01% | 2091 |
|
|
2023
Q4 | $4.43M | Buy |
218,662
+30,268
| +16% | +$613K | ﹤0.01% | 2363 |
|
|
2023
Q3 | $3.35M | Buy |
188,394
+35,730
| +23% | +$635K | ﹤0.01% | 2427 |
|
|
2023
Q2 | $2.76M | Buy |
152,664
+13,513
| +10% | +$244K | ﹤0.01% | 2453 |
|
|
2023
Q1 | $1.75M | Buy |
139,151
+600
| +0.4% | +$7.54K | ﹤0.01% | 2560 |
|
|
2022
Q4 | $2.03M | Buy |
138,551
+2,171
| +2% | +$31.8K | ﹤0.01% | 2568 |
|
|
2022
Q3 | $2.34M | Buy |
136,380
+43,647
| +47% | +$747K | ﹤0.01% | 2541 |
|
|
2022
Q2 | $1.35M | Buy |
92,733
+44,150
| +91% | +$645K | ﹤0.01% | 2687 |
|
|
2022
Q1 | $818K | Buy |
48,583
+1,402
| +3% | +$23.6K | ﹤0.01% | 2928 |
|
|
2021
Q4 | $1.06M | Buy |
47,181
+415
| +0.9% | +$9.34K | ﹤0.01% | 2885 |
|
|
2021
Q3 | $1.01M | Buy |
46,766
+193
| +0.4% | +$4.16K | ﹤0.01% | 2871 |
|
|
2021
Q2 | $1.35M | Buy |
46,573
+4,950
| +12% | +$143K | ﹤0.01% | 2829 |
|
|
2021
Q1 | $1.34M | Buy |
41,623
+4,400
| +12% | +$142K | ﹤0.01% | 2759 |
|
|
2020
Q4 | $1.54M | Buy |
+37,223
| New | +$1.54M | ﹤0.01% | 2666 |
|